News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inotek Pharmaceuticals Corporation to Expand Phase 2 Clinical Trial in Glaucoma Based on Promising Preliminary Results



7/21/2011 10:25:48 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension. Based on the achievement of this milestone, Inotek’s investors have committed the final tranche of their previous $20 million funding round and have committed an additional $3.7 million to expand the final portion of the ongoing clinical trial by increasing the number of subjects and the duration of treatment in the final phase.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES